Abstract 2737
Background
Well-differentiated liposarcomas (WDLPS) can be difficult to distinguish from lipomas. Currently, this distinction is made by testing for MDM2-amplification, which requires a biopsy. The aim of this study was to non-invasively predict the MDM2-amplification status using radiomics, i.e. a combination of quantitative imaging features and machine learning techniques, thereby differentiating between lipomas and WDLPS.
Methods
Patients with a lipoma or WDLPS, a known MDM2-amplification status and a pre-treatment T1-weighted MRI scan who were referred to or diagnosed at the Erasmus MC from 2009-2018 were included. When available, other sequences, e.g. T2-weighted (fat-saturated) MRI, were included in the radiomics analysis. Imaging features describing intensity, shape, orientation and texture were extracted from the tumor segmentations; age, gender, tumor depth and tumor localization were added as semantic features. Classification was performed using an ensemble of various machine learning approaches. Evaluation was performed through 100x random-split cross-validation.
Results
We included 116 patients: 58 patients with lipoma and 58 patients with WDLPS. The dataset originated from 41 MRI-scanners, resulting in large heterogeneity in imaging hardware and acquisition protocols. The best performing radiomics approach to differentiate between WDLPS and lipomas, based on T1-weighted imaging only, resulted in a mean [95% confidence interval] AUC of 0.75 [0.65-0.86], accuracy of 0.68 [0.59-0.77], sensitivity of 0.63 [0.48-0.78] and specificity of 0.73 [0.59-0.87]. A model based on the combination of imaging and semantic featured showed only a minor and non-significant improvement in performance.
Conclusions
There is a significant relationship between a radiomics signature, consisting of a combination of quantitative MRI features, and the MDM2-amplification status. Although further optimization and validation is needed for the transition to clinical practice, radiomics has appeared to be a promising, non-invasive approach for the classification of WDLPS and lipomas.
Clinical trial identification
Editorial acknowledgement
M.Vos and M.P.A. Starmans contributed equally to this study.
Legal entity responsible for the study
The authors.
Funding
Stichting Coolsingel, Netherlands Organisation for Scientific Research, Dutch Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract